PL3456720T3 - Nowa postać soli krystalicznej 2,2-dimetylo-6-((4-((3,4,5-trimetoksyfenylo)amino)-1,3,5-triazyn-2-ilo)amino)-2h-pirydo[3,2-b][1,4]oksazyn-3(4h)-onu do zastosowań medycznych - Google Patents

Nowa postać soli krystalicznej 2,2-dimetylo-6-((4-((3,4,5-trimetoksyfenylo)amino)-1,3,5-triazyn-2-ilo)amino)-2h-pirydo[3,2-b][1,4]oksazyn-3(4h)-onu do zastosowań medycznych

Info

Publication number
PL3456720T3
PL3456720T3 PL17796477T PL17796477T PL3456720T3 PL 3456720 T3 PL3456720 T3 PL 3456720T3 PL 17796477 T PL17796477 T PL 17796477T PL 17796477 T PL17796477 T PL 17796477T PL 3456720 T3 PL3456720 T3 PL 3456720T3
Authority
PL
Poland
Prior art keywords
amino
oxazin
trimethoxyphenyl
triazin
pyrido
Prior art date
Application number
PL17796477T
Other languages
English (en)
Inventor
Vladimir Evgenievich Nebolsin
Fedor Nikolaevich NOVIKOV
Germes Grigorievich CHILOV
Oleg Valentinovich STROGANOV
Viktor Sergeevich STROILOV
Ilya Yurievich TITOV
Original Assignee
Limited "Molecular Technologies"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Limited "Molecular Technologies" filed Critical Limited "Molecular Technologies"
Publication of PL3456720T3 publication Critical patent/PL3456720T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL17796477T 2016-05-13 2017-05-10 Nowa postać soli krystalicznej 2,2-dimetylo-6-((4-((3,4,5-trimetoksyfenylo)amino)-1,3,5-triazyn-2-ilo)amino)-2h-pirydo[3,2-b][1,4]oksazyn-3(4h)-onu do zastosowań medycznych PL3456720T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2015147258A RU2621187C1 (ru) 2016-05-13 2016-05-13 Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2н-пиридо[3,2-в][1,4]оксазин-3(4н)-она для медицинского применения
EP17796477.2A EP3456720B1 (en) 2016-05-13 2017-05-10 Novel crystalline salt form of 2,2-dimethyl-6-((4-((3,4,5-trimethoxyphenyl)amino)-1,3,5-triazin-2-yl)amino)-2h-pyrido[3,2-b][1,4]oxazin-3(4h)-one for medical application
PCT/RU2017/050037 WO2017196210A1 (ru) 2016-05-13 2017-05-10 Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2h-пиридо[3,2-b][1,4]оксазин-3(4h)-она для медицинского применения

Publications (1)

Publication Number Publication Date
PL3456720T3 true PL3456720T3 (pl) 2021-12-06

Family

ID=59032468

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17796477T PL3456720T3 (pl) 2016-05-13 2017-05-10 Nowa postać soli krystalicznej 2,2-dimetylo-6-((4-((3,4,5-trimetoksyfenylo)amino)-1,3,5-triazyn-2-ilo)amino)-2h-pirydo[3,2-b][1,4]oksazyn-3(4h)-onu do zastosowań medycznych

Country Status (13)

Country Link
US (1) US10745414B2 (pl)
EP (1) EP3456720B1 (pl)
JP (1) JP6980299B2 (pl)
KR (1) KR102522102B1 (pl)
CN (1) CN109526221B (pl)
AU (1) AU2017264302B2 (pl)
CA (1) CA3023231A1 (pl)
DK (1) DK3456720T3 (pl)
EA (1) EA037460B1 (pl)
ES (1) ES2892274T3 (pl)
PL (1) PL3456720T3 (pl)
RU (1) RU2621187C1 (pl)
WO (1) WO2017196210A1 (pl)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
PL1656372T3 (pl) * 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
US8227455B2 (en) * 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
RU2509770C2 (ru) * 2012-06-22 2014-03-20 Общество с ограниченной ответственностью "Молекулярные Технологии" Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
WO2015047124A1 (ru) * 2013-09-26 2015-04-02 Общество с ограниченной ответственностью "Молекулярные Технологии" Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных

Also Published As

Publication number Publication date
AU2017264302A1 (en) 2019-01-03
JP6980299B2 (ja) 2021-12-15
RU2621187C1 (ru) 2017-06-01
AU2017264302B2 (en) 2021-05-27
US20190292198A1 (en) 2019-09-26
EP3456720B1 (en) 2021-06-30
KR102522102B1 (ko) 2023-04-13
EP3456720A1 (en) 2019-03-20
CA3023231A1 (en) 2017-11-16
CN109526221A (zh) 2019-03-26
EA201892589A1 (ru) 2019-04-30
KR20190005996A (ko) 2019-01-16
EA037460B1 (ru) 2021-03-30
JP2019515053A (ja) 2019-06-06
DK3456720T3 (da) 2021-09-27
EP3456720A4 (en) 2019-10-30
WO2017196210A1 (ru) 2017-11-16
CN109526221B (zh) 2022-06-21
ES2892274T3 (es) 2022-02-03
US10745414B2 (en) 2020-08-18

Similar Documents

Publication Publication Date Title
IL279910A (en) Crystal forms of 5-chloro-ene 4-[2-(dimethylphosphoryl)phenyl]-ene 2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidin-2- 4-diamine
ZA201802797B (en) 2-(het)aryl-substituted condensed bicyclic heterocyclic derivatives as pest control agents
NI201600152A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
MX2018013235A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil )etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida.
HK1207645A1 (en) Substituted 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives useful for the treatment of (inter alia) alzheimers disease () 34--2h-[12-a] -16-
HUE052454T2 (hu) CDK4 inhibitorok 2-((5-(1-(3-(metilszulfonil)propil)piperidin-4-il)piridin-2-il)amino)-pirido[2,3-D]pirimidin-7(8H)-on származékok és rokonvegyületek tumorok kezelésére
DK3160958T3 (da) Krystallinske salte af (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidin-4-carboxamid
SI3250208T1 (sl) 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo (1,2-A)pirido(3,4-E)pirimidin-5-(4H)-on in njegove soli ter njihova uporaba v terapiji
DK3110840T3 (da) A22k, desb27, b29r, des b30, ved epsilon-position af lysin 22 acyleret human insulinanalog
MD3288940T2 (ro) Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA
IL271399A (en) Methods for the preparation of heterocyclic 3,1-benzodioxole compounds
IL259617B (en) Methods for the preparation of 3,1-benzodioxole heterocyclic compounds
DK3077389T3 (da) Krystallinsk form af (s)-(2-(6-chlor-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanon og dens anvendelse som orexinreceptorantagonister
GB2541840B (en) Ophthalmic composition for the treatment of ocular infection
PL3558954T3 (pl) Ulepszony sposób wytwarzania chlorowodorku r-6-hydroxy-8-[1-hydroksy-2-[2-(4-metoksyfenylo)-1,1-dimetyloetyloaminoetylo]-2h-1,4-benzoksazyno-3(4h)-onu
IL269666B1 (en) Crystalline form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol, its preparation and use at him
ZA201804663B (en) C-glycoside derivatives having fused phenyl ring or pharmaceutically acceptable salts thereof, method for preparing the same and pharmaceutical composition comprising the same
PL3456720T3 (pl) Nowa postać soli krystalicznej 2,2-dimetylo-6-((4-((3,4,5-trimetoksyfenylo)amino)-1,3,5-triazyn-2-ilo)amino)-2h-pirydo[3,2-b][1,4]oksazyn-3(4h)-onu do zastosowań medycznych
DK3398946T3 (da) Salt af morpholin-derivat og krystallin form deraf, samt fremstillingsfremgangsmåde, farmaceutisk sammensætning og anvendelse af samme
DK3842436T3 (da) Farmaceutisk sammensætning omfattende imidazopyridin- eller imidazotriazinderivater til anvendelse i behandlingen af skizofreni
IL263299A (en) Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
SI3484892T1 (sl) Derivati 1,2,4-triazolo-(3,4-B)-1,3,4-tiadiazola
BR112018016208A2 (pt) compostos heterocíclicos, em particular derivados 2-oxo-4,4,5,5,6,6,7,7-octahidrobenzoxazol, e seus usos como compostos antibacterianos
MX2016013911A (es) Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido.
ZA201902791B (en) 2-(het)aryl-substituted condensed bicyclic heterocycle derivatives as pest control agents